BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 2, 2014, Pages

  Bohn, Olga L ^a   Hsu, Katharine ^a   Hyman, David M ^a   Pignataro, Daniela S ^a   Giralt, Sergio ^a   Teruya Feldstein, Julie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRAF mutation; Multiple myeloma; Refractory; Relapse; Vemurafenib

Indexed keywords

B RAF KINASE; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CD3 ANTIGEN; CD30 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; LENALIDOMIDE; MELPHALAN; MYC PROTEIN; PROTEIN P53; SYNDECAN 1; THALIDOMIDE; VEMURAFENIB; BRAF PROTEIN, HUMAN;

ABDOMINAL RADIOGRAPHY; ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CLONAL EVOLUTION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENOTYPE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERPHASE; INTESTINE TUMOR; MALE; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMACYTOMA; POSITRON EMISSION TOMOGRAPHY; SMALL INTESTINE RESECTION; TREATMENT RESPONSE; AMINO ACID SUBSTITUTION; CELL DIFFERENTIATION; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; PATHOLOGY; PLASMA CELL; TUMOR RECURRENCE;

AMINO ACID SUBSTITUTION; CELL DIFFERENTIATION; CLONAL EVOLUTION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; NEOPLASM RECURRENCE, LOCAL; PLASMA CELLS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84896347450     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.12.003     Document Type: Article

References (14)

1. C. Wellbrock, and A. Hurlstone BRAF as therapeutic target in melanoma Biochem Pharmacol 80 2010 561 567.
2. J.A. Sosman, K.B. Kim, and L. Schuchter et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714.
3. G.V. Long, A.M. Menzies, and A.M. Nagrial et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 2011 1239 1246.
4. S. Velho, C. Moutinho, and L. Cirnes et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8 2008 255.
5. M. Das Thakur, F. Salangsang, and A.S. Landman et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255.
6. M.A. Chapman, M.S. Lawrence, and J.J. Keats et al. Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472.
7. M. Andrulis, N. Lehners, and D. Capper et al. Targeting the BRAF V600E mutation in multiple myeloma Cancer Discov 3 2013 862 869.
8. E. Colomba, Z. Helias-Rodzewicz, and A. Von Deimling et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing J Mol Diagn 15 2013 94 100.
9. M.C. Ravnan, and M.S. Matalka Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma Clin Ther 34 2012 1474 1486.
10. A. Sharma, S.R. Shah, and H. Illum et al. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies Drugs 72 2012 2207 2222.
11. N.J. Bahlis Darwinian evolution and tiding clones in multiple myeloma Blood 120 2012 927 928.
12. J.B. Egan, C.X. Shi, and W. Tembe et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides Blood 120 2012 1060 1066.
13. J.J. Keats, M. Chesi, and J.B. Egan et al. Clonal competition with alternating dominance in multiple myeloma Blood 120 2012 1067 1076.
14. B.A. Walker, C.P. Wardell, and L. Melchor et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma Blood 120 2012 1077 1086.